The Italian Version of the ALS Depression Inventory-12

Debora Pain1*, Edoardo Nicolò Aiello2,3*, Marcello Gallucci4, Massimo Miglioretti4† and Gabriele Mora1†

1 Istituti Clinici Scientifici Maugeri, IRCCS, Neurorehabilitation Department of Milano Institute, Milan, Italy,
2 School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy,
3 PhD Program in Neuroscience, University of Milano-Bicocca, Monza, Italy,
4 Department of Psychology, University of Milano-Bicocca, Milan, Italy

Introduction: Depression is a comorbidity in patients with amyotrophic lateral sclerosis (ALS). However, its diagnosis is challenged by the co-occurrence of a similar frontotemporal (FT) behavioral symptom—i.e., apathy. Moreover, its psychometric evaluation is confounded by motor disabilities. This study aimed at investigating psychometric properties and feasibility of the ALS Depression Inventory (ADI-12), a self-report questionnaire set up for this issue—as measuring mood changes without referring to movement.

Methods: Eighty-five ALS patients were administered the ADI-12 and underwent cognitive (Mini-Mental State Examination, MMSE), quality of life (McGill Quality of Life Questionnaire, MQoL) and further anxiety/mood (Hospital Anxiety and Depression Scale, HADS) assessments. Reliability, validity, sensitivity, and specificity of the ADI-12 were explored.

Results: Principal component analyses revealed two related components—“Negative Mood and Lack of Energy” (ME) and “Anhedonia” (A). Both components and the inventory as a whole were internally consistent and highly related to HADS-D. ADI-12-total score was also associated with HADS-A. ADI-12 measures were inversely related to MQoL. ADI-12-total/sub-scales were not related to either MMSE or disease-related outcomes. Estimates of depression yielded by HADS-D and ADI-12 were 11.1 and 35.3%.

Discussion: The ADI-12 is a valid, reliable and usable feasible tool to assess depression in Italian ALS patients independently from motor disabilities. Its interplay with psycho-social outcomes is in agreement with previous studies. The lack of association with cognition suggests that the ADI-12 is partially independent from FT spectrum disorders. The disagreement in depression rates between the ADI-12 and HADS-D suggests the need to ALS-specific mood scales.

Keywords: amyotrophic lateral sclerosis, depression, psychometrics, apathy, neuropsychology, frontotemporal dementia

INTRODUCTION

Depression is a well-known psychiatric co-morbidity in patients affected by amyotrophic lateral sclerosis (ALS) (1, 2)—although its etiology still needs to be clarified (3). A diagnosis of depression in ALS population may be confounded by the presence of concomitant apathy (3)—a frontotemporal (FT) behavioral symptom involving up to 50% of ALS patients (4).
Screening for depressive symptoms should not be neglected in ALS patients, as negatively influencing disease prognosis and survival (5). However, psychometric evaluation of mood in ALS patients is challenging as widely used scales to assess depression include items that often refer to motor abilities (6). To adopt assessments not depending on motor impairment is crucial, as its confounding effect has been linked to the heterogeneity in estimating the prevalence of depression in this population (1). Nonetheless, according to recent meta-analytic evidence (7), depressive disorders are estimated to be moderately prevalent in ALS patients (34%).

The ALS Depression Inventory-12 (ADI-12) (8, 9) is an ALS-specific, 12-item, self-report questionnaire whose items measure mood changes without referring to motor function.

This study aimed at investigating psychometric properties and feasibility of the ADI-12 in a cohort of Italian ALS patients.

METHODS

Participants

Eighty-five ALS patients referred to Istituti Clinici Scientifici Maugeri, IRCCS Milano, Italy, were consecutively recruited. Exclusion criteria were major internal, neurologic or (other) psychiatric disorders. Participants’ background and clinical features are shown in Table 1. The study was approved by the local Ethical Committee. Participants provided written informed consent to participation.

Materials

Items were back-translated by two independent Authors (D.P. and M.M.). Inter-rater agreement was assessed and discrepancies were solved through discussion. ADI-12 items are reported through a four-point Likert scale; items 5-9, 11, and 12 are negatively worded.

The protocol for the Italian ADI-12 will be provided to interested clinicians upon request to the corresponding Author.

In addition, patients were tested for cognition (Mini-Mental State Examination; MMSE) (11–13), quality of life (McGill Quality of Life Questionnaire; MQoL) (14), and mood/anxiety (Hospital Anxiety and Depression Scale; HADS) (15). HADS items referring to movement were discussed with patients during administration in order to avoid biases in responses; a similar approach has been adopted (deleting those motor-related items) (16).

Statistical Analyses

SPSS 27 (17) was used to analyze data.

Raw variables were descriptively checked for normality to determine whether to adopt linear models or non-parametric alternatives (18).

Factorial structure was assessed by means of principal component analyses (PCA). Convergent validity was tested by means of parametric/non-parametric correlational techniques. Reliability was assessed as internal consistency through Cronbach’s $\alpha$.

RESULTS

An obliquely rotated PCA (Table 2) yielded two correlated components ($r = 0.48$) cumulatively explaining 61.02% of variance—the first identified as “Negative Mood and Lack of Energy” (ADI-12-ME; N = 7 items), whereas the second as “Anhedonia” (ADI-12-A; N = 5 items) (9). Items of the two components can be summed up to obtain the 12-item inventory. No clearly ambiguous items were detected when inspecting the pattern matrix (primary loadings $\geq 0.3$), with the exception of item 10, whose ratio between its primary ($r = -0.47$) and secondary ($r = -0.26$) loadings was slightly lower than 2 (1.81).

According to the aforementioned sub-division, both ADI-12-ME and ADI-12-A items proved to be highly internally consistent.

| TABLE 1 | Patients’ background and clinical data. |
|---------|----------------------------------------|
| N       | 85                                     |
| Age (years) | 62.3 ± 9.5 (37-79)                |
| Sex (M/F)  | 51.8/48.2%                           |
| Education |                          |
| Elementary School | 25.9%            |
| Junior high School | 41.2%              |
| High school       | 25.9%                             |
| University        | 7.1%                               |
| Occupation       |                                      |
| Retired           | 58.8%                             |
| Unoccupied        | 2.4%                              |
| Occupied          | 38.8%                             |
| Age at onset (years) | 59.7 ± 9.6 (35-77)            |
| Age at diagnosis (years) | 60.7 ± 9.6 (35-77)        |
| Diagnostic delay (years) | 0.99 ± 0.63 (0-4)           |
| Disease duration (years) | 1.6 ± 1.73 (0-13)          |
| Site of onset     |                                      |
| Bulbar            | 20%                                |
| Spinal            | 80%                                |
| Phenotype*        |                                      |
| Classical         | 76.2%                              |
| Bulbar            | 16.7%                              |
| Pyramidal         | 3.6%                               |
| FAS               | 2.4%                               |
| FLS               | 1.2%                               |
| MMSE              | 27.61 ± 2.1 (23-30)                |
| ADI-12            | 25.56 ± 6.61 (13-43)              |
| HADS-A            | 6.59 ± 3.67 (1-17)                 |
| HADS-D            | 5.14 ± 3.14 (0-14)                |
| MQoL              |                                      |
| Total             | 6.8 ± 1.25 (3.54-9.5)              |
| Physical          | 5.81 ± 2.27 (1.25-10)              |
| Psychological     | 5.03 ± 1.95 (0.83-9.5)             |
| Existential       | 7.21 ± 1.64 (0-10)                 |
| Support           | 8.11 ± 1.59 (0-10)                 |

FAS, flail arm syndrome; FLS, flail leg syndrome; MMSE, Mini-Mental State Examination; ADI-12, ALS Depression Inventory-12; HADS-A/-D, Hospital Anxiety and Depression Scale-Anxiety/-Depression; MQoL, McGill Quality of Life Questionnaire; *Piemonte and Valle d’Aosta Register for ALS (PARALS) (10).

The optimal cut-off for the ADI-12 was identified through receiver-operating curve (ROC) analyses by computing Youden index (19).
(Cronbach’s α = 0.86 and = 0.84, respectively), as well as the inventory as a whole (Cronbach’s α = 0.9).

All ADI-12 measures displayed medium-to-large correlation with HADS-D scores; only ADI-12-total and -ME scores were significantly related to HADS-A (Table 3).

All ADI-12 measures proved to be inversely associated with MQoL-total and sub-scale scores, with the exception of MQoL-Support (Table 3).

By regarding an HADS-D score ≥10 as suggestive of depression (15), an optimal cut-off (88.9% of sensitivity and 69.4% of specificity; J = 0.58) for the ADI-12 as a whole (i.e., the sum of ADI-A and ADI-ME items) was set at 27.5 (AUC = 0.87; SE = 0.06; 95% CI [0.75,0.98]) (Figure 1). When addressing a cut-off of 28, 35.3% of the present patients were classified as having depressive symptoms—whereas, by contrast, HADS-D detected depressed mood in 11.1% of the cohort.

ADI-12 measures proved not to be related with MMSE scores. No association was detected between ADI-12 measures and either disease duration, diagnostic delay, clinical phenotype or site of onset.

DISCUSSION

The present study provides clinicians with evidence regarding the psychometric goodness and feasibility of the ADI-12 for detecting depressive symptoms in ALS patients. The ADI-12 indeed showed high internal consistency as well as both construct and convergent validity. According to the present results, a cut-off of 28 is proposed for normal range.

The discrepancies reported here in detection rates between HADS-D (11.1%) and the ADI-12 (35.3%) support the notion that ALS-specific, motor-free tools are needed when screening for depression in this population. In this regards, motor-related HADS-D items were actively discussed with patients during administration procedures—i.e., potential biases were to an extent controlled for.

The construct underlying the ADI-12 has been originally identified as mono-factorial—encompassing depressed mood, lack of energy and anhedonia (9). Conversely, the present work hints at anhedonia being separable from depressed mood and asthenia in this population.

The lack of association between ADI-12 scores and the MMSE suggests that depression levels as assessed by the former might be to an extent independent from FT spectrum disorders (3). Thereupon, the ADI-12 is likely to help clinicians differentiating psychogenic/reactive depression from behavioral, apathy-related symptoms in this population.

Moreover, the present findings do not support the previously-endorsed notion of longer diagnostic delay and bulbar onset/involvement as risk factors for depression in ALS patients (21, 22). These inconsistencies are likely

| Table 2 | Loadings of ADI-12 items on the two components as yielded by PCA. |
|---|---|
| Item | Component ME | Component A |
| 1 | I am happy and I smile often. | -0.86 | 0.10 |
| 2 | I can appreciate life despite my circumstances. | -0.29 | -0.63 |
| 3 | I can get away from it all and I am often relaxed. | -0.85 | 0.18 |
| 4 | I feel alive and vital. | -0.63 | -0.24 |
| 5 | More often than not I am sad. | 0.73 | 0.1 |
| 6 | I have lost all interest in family and friends. | -0.14 | 0.89 |
| 7 | Most often I feel empty. | -0.02 | 0.78 |
| 8 | There is nothing that I look forward to or that I can enjoy. | 0.06 | 0.84 |
| 9 | I often feel lost and abandoned and don’t know how to carry on. | 0.81 | 0.02 |
| 10 | I look forward to every new day. | -0.47 | -0.26 |
| 11 | I often wish I were dead. | 0.22 | 0.58 |
| 12 | I feel like I have lost all of my energy. | 0.64 | 0.2 |

ADI-12, ALS Depression Inventory-12; ME, Negative Mood and Lack of Energy component of ADI-12; A, Anhedonia component of ADI-12; PCA, principal component analysis. They are the acronyms for the psychometric measures.

| Table 3 | Correlation coefficients between ADI-12 and psycho-social measures. |
|---|---|
| | HADS-A | HADS-D | MQoL total | MQoL physical | MQoL psychological | MQoL existential† | MQoL support† |
| ADI-12 total | 0.35** | 0.54** | -0.54** | -0.43** | -0.53** | -0.41** | -0.09 |
| ADI-12-ME | 0.42** | 0.53** | -0.59** | -0.42** | -0.57** | -0.46** | -0.15 |
| ADI-12-A | 0.18 | 0.42** | -0.34** | -0.33** | -0.35** | -0.26* | -0.01 |

ADI-12, ALS Depression Inventory-12; ME, Negative Mood and Lack of Energy component of ADI-12; A, Anhedonia component of ADI-12; HADS-A/D, Hospital Anxiety and Depression Scale-Anxiety/Depression; MQoL, McGill Quality of Life Questionnaire. †Spearman’s coefficients; *significant at α = 0.05; **significant at α = 0.01.
to be due to the fact that, within studies reporting such findings, psychometric measures of depression were not motor-free (21, 22).

Finally, data here presented again support the interplay between mood and quality of life in ALS patients (23). More specifically, depression levels were strongly associated with a decrease of both physical and psychological well-being but not to the degree of perceived social support, contrarily to previous findings (24). This latter discrepancy might be again linked to the adoption of non-ALS-specific tools for assessing depressive symptoms (24).

Future investigations may focus on: (1) exploring the interplay between the ADI-12 and ALS-specific cognitive screeners (25–29); (2) testing the divergent validity of the ADI-12 against ALS-specific/motor-free scales of apathy (30, 31); (3) investigating the association between the ADI-12 and tools designed to detect FT-like behavioral changes (32, 33); (4) further examining how ADI-12 scores relate motor-functional impairment in ALS patients (34).

In conclusion, the adoption of the ADI-12 as a motor- and FT impairment-independent tool to screen depression in ALS patients should be encouraged in clinical practice.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Istituti Clinici Scientifci Maugeri, Pavia, Italy. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

MM, MG, and EA contributed to methodology and statistics. DP contributed to study conception and design, data collection and methodology and statistics. GM supervised the whole process. All the authors contributed to manuscript drafting.

ACKNOWLEDGMENTS

The authors are grateful to patients for their participation in this study. The authors would like to thank Drs. Paola Cerutti and Gisella Bruletti for their contribution to data collection.

REFERENCES

1. Atassi N, Cook A, Pineda CM, Yerramilli-Rao P, Pulley D, Cudkowicz M. Depression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. (2011) 12:109–12. doi: 10.3109/17482968.2011.536839
2. Roos E, Marioni D, Ingre C, Lundholm C, Wirdefeldt K, Roos PM, et al. Depression in amyotrophic lateral sclerosis. Neurology. (2016) 86:2271–7. doi: 10.1212/WNL.000000000002671
3. Zucchi E, Ticozzi N, Mandrioli J. Psychiatric symptoms in amyotrophic lateral sclerosis: beyond a motor neuron disorder. Front Neurol. (2019) 13:175. doi: 10.3389/fnins.2019.00175
4. Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, et al. Amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. (2017) 18:153–74. doi: 10.1080/21678421.2016.1267768
5. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. (2009) 10:310–23. doi: 10.3109/1748296802566824
6. Ferentinos P, Paparrigopoulos T, Rontzos M, Zouvelou V, Alexakis T, Evdokimidis I. Prevalence of major depression in ALS: comparison of a semi-structured interview and four self-report measures. Amyotroph Lateral Scler. (2011) 12:297–302. doi: 10.3109/17482968.2011.556744
7. Heidari ME, Nadali J, Parouhan A, Azarafraz M, Irvani SSN, Gharebaghi A. Prevalence of depressive disorder among amyotrophic lateral sclerosis (ALS) patients: systematic review and meta-analysis. J Affect Disord. (2021) 287:181–90. doi: 10.1016/j.jad.2021.03.015
8. Kübler A, Winter S, Ludolph AC, Hautzinger M, Birbaumer N. Severity of depressive symptoms and quality of life in patients with amyotrophic lateral sclerosis. Neurorehabil Neural Repair. (2005) 19:182–93. doi: 10.1177/1545968305276583
9. Hammer EM, Häcker S, Hautzinger M, Meyer TD, Kübler A. Validity of the ALS-Depression-Inventory (ADI-12)—a new screening instrument for depressive disorders in patients with amyotrophic lateral sclerosis. J Affect Disord. (2008) 109:213–9. doi: 10.1016/j.jad.2007.11.012
10. Chiò A, Calvo A, Moglia C, Mazzini I, Mora G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. (2011) 82:740–6. doi: 10.1136/jnnp.2010.239592
11. Measso G, Cavarzeran F, Zappala G, Lebowitz BD, Crook TH, Pirozzolo FJ, et al. The Mini-Mental State Examination: normative
study of an Italian random sample. Dev Neuropsychol. (1993) 9:77–85. doi: 10.1080/8756549109540545

12. Magni E, Binetti G, Blanchetti A, Rozzini R, Trabucchi M. Mini-Mental State Examination: a normative study in Italian elderly population. Eur J Neurol. (1996) 3:198–202. doi: 10.1111/j.1468-1331.1996.tb00423.x

13. Gosselt IK, Nijboer TC, Van Es M. An overview of screening instruments for cognition and behavior in patients with ALS: selecting the appropriate tool for clinical practice. Amyotroph Lateral Scler Frontotemporal Degener. (2020) 21:324–36. doi: 10.1080/21678421.2020.1732424

14. Goss, I., Giori G., Allesi A., Fini M. Italian validation of the McGill Quality of Life Questionnaire (MQOL-It). Giornale Italiano di Medicina del Lavoro ed Ergonomia. (2010) 32:588–62.

15. Costantini M, Musso M, Viterbini G, Bonci F, Del Mastro L, Garrone O, et al. Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer. (1999) 7:121–7. doi: 10.1007/s005200050241

16. Gibbons CJ, Mills RJ, Thornton EW, Ealing J, Shaw PJ, et al. Rasch analysis of the hospital anxiety and depression scale (HADS) for use in motor neurone disease. Health Qual Life Outcomes. (2011) 9:1–8. doi: 10.1186/1477-7525-9-82

17. IBM Corp. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp. (2021).

18. Kim HY. Statistical notes for clinical researchers: assessing normal distribution (2) using skewness and kurtosis. Restor Dentist Endod. (2013) 38:52–4. doi: 10.5395/rde.2013.38.1.52

19. Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, et al. Apathy is not depression. J Neuropsychiatr Clin Neurosci. (1998) 10:314–9. doi: 10.1176/jnp.10.3.314

20. Linnebach T, Gräfle E, Tigges S, Bleich S, Neundörfer B, Kornhuber J, et al. Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer. (1999) 7:121–7. doi: 10.1007/s005200050241

21. Gibbons CJ, Mills RJ, Thornton EW, Ealing J, Mitchell JD, Shaw PJ, et al. Rasch analysis of the hospital anxiety and depression scale (HADS) for use in motor neurone disease. Health Qual Life Outcomes. (2011) 9:1–8. doi: 10.1186/1477-7525-9-82

22. IBM Corp. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp. (2021).

23. Poletti B, Solca F, Carelli L, Madotto L, Lafronz A, Faini A, et al. The validation of the Italian Edinburgh cognitive and behavioural ALS screen (ECAS). Amyotroph Lateral Scler Frontotemporal Degener. (2016) 17:489–98. doi: 10.1080/21678421.2016.1183679

24. Ciciliano M, Trojano L, Troisi F, Greco R, Santoro M, Basile G, et al. Edinburgh Cognitive and Behavioural ALS Screen (ECAS)-Italian version: regression based norms and equivalent scores. Neurol Sci. (2017) 38:1059–68. doi: 10.1007/s10072-017-2919-4

25. Tremolizzo L, Lizio A, Santangelo G, Diamanti S, Lunetta C, Gerardi F, et al. ALS Cognitive Behavioral Screen (ALS-CBS): normative values for the Italian population and clinical usability. Neurol Sci. (2020) 41:835–41. doi: 10.1007/s10072-019-04154-1

26. Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. (2014) 15:9–14. doi: 10.3109/21678421.2013.805784